VEGFA and neoplasm: We suggest that deficiency of platelet-derived growth factors in mice subjected to dual anti-platelet therapy with ASA+Cl could contribute to dysfunction of the primary tumour microvasculature what could drive VM by VEGF/VEGFR1-dependent pathway [41, 42] to support tumour perfusion.